论文部分内容阅读
日本名古屋大学医学院的Rohno报告:干扰素-α-2a(?)证明是治疗多发性骨髓廇的有效药物之一。 干扰素-α-2a治疗多发性骨髓瘤的47例患者中,10例得到部分缓解(21.3％),5例得到轻度缓解。总有效者15人(31.9％)。这个结果和以前报道的用白细胞干扰素和成人纤维细胞干扰素—beta治疗的疗效相似。 干扰素治疗的有效率并没有完全达到苯丙氨酸氮芥的有效率(25—40％),但对曾用苯丙氨酸氮芥和其他抗肿瘤药治疗或普通疗法疗效差的病人仍然有效。因无交叉抗药性,干扰素和常规抗肿瘟疗法的联合使
Rohno of the Nagoya University School of Medicine in Japan reports that interferon-α-2a (?) Has been shown to be one of the potent drugs in the treatment of multiple myeloma. Of the 47 patients treated with interferon-α-2a for multiple myeloma, 10 were partially relieved (21.3%) and 5 were slightly relieved. The total effective 15 (31.9%). This result is similar to the previously reported treatment with leukocyte interferon and adult fibroblast interferon-beta. The effectiveness of interferon treatment did not fully reach the efficacy of melphalan (25-40%), but for those who had been treated with melphalan and other antineoplastic agents or poor efficacy of conventional therapy is still effective. Because there is no cross-resistance, interferon and conventional anti-lmporal therapy combined